Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

A Randomized, Double Blind, Parallel Group, Placebo-controlled Trial to Study the Efficacy and Safety of Two Oral Doses of Prurisol Administered Twice Daily for Twelve Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis

This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to severe chronic plaque psoriasis.

Study Overview

• Status: Completed
• Conditions: Chronic Stable Plaque Psoriasis
• Intervention / Treatment: Drug: Placebo; Drug: 300 mg (150 mg BID); Drug: 400 mg (200 mg BID)

Detailed Description

This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to severe chronic plaque psoriasis.

Approximately 189 study participants will be enrolled. Subjects will be randomly assigned to one of three treatment groups in a 3:3:1 randomization ratio, respectively.

• Group A (n=81): Prurisol 150 mg bid
• Group B (n=81): Placebo
• Group C (n=27): Prurisol 200 mg bid Outpatient subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy will be recruited to the study. Study participants are required to have a Psoriasis Area and Severity Index (PASI) score ≥ 12, body surface area involvement ≥ 10%, and a static Physician's Global Assessment (sPGA) of moderate or severe (score of 3 or 4).

A subject studied under this clinical protocol will commence with a screening period of up to 4 weeks, a treatment period of 12 weeks, and a follow-up period of 4 weeks ending with an End of Study evaluation.

During treatment, subjects will return to the study center every 2 weeks. Efficacy assessments, including physician and patient rated endpoints, will be measured throughout the study. Safety and tolerability will be assessed by ascertainment of AEs and results of clinical laboratory testing, vital signs assessments, and need for concomitant medications.

At a subset of sites, blood samples for determination of plasma concentrations of Prurisol (abacavir glycolate) and abacavir, it's metabolite, will be obtained from subjects who consent to provide these samples. At selected sites, for those subjects consenting to photography, standardized digital photographs will be obtained for illustrative purposes.

• Study Type: Interventional
• Enrollment (Actual): 199
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Glendale, Arizona, United States, 85308
      • Study Site
  • Arkansas
    • Hot Springs, Arkansas, United States, 71913
      • Study Center
    • Rogers, Arkansas, United States, 72758
      • Clinical Study Site
  • California
    • Los Angeles, California, United States, 90017
      • Study Center
    • Los Angeles, California, United States, 90036
      • Study Site
    • Murrieta, California, United States, 92562
      • Clinical Study Site
    • Oceanside, California, United States, 92056
      • Clinical Study Site
    • Sherman Oaks, California, United States, 91403
      • Study Site
  • Colorado
    • Denver, Colorado, United States, 80209
      • Study Site
    • Denver, Colorado, United States, 80210
      • Clinical Study Site
  • Florida
    • Port Orange, Florida, United States, 32127
      • Study Site
    • Tampa, Florida, United States, 33609
      • Clinical Study Site
  • Georgia
    • Savannah, Georgia, United States, 31406
      • Study Site
  • Illinois
    • Arlington Heights, Illinois, United States, 60005
      • Study Center
  • Indiana
    • South Bend, Indiana, United States, 46617
      • Clinical Study Site
  • Kansas
    • Overland Park, Kansas, United States, 66215
      • Study Center
  • Kentucky
    • Louisville, Kentucky, United States, 40217
      • Study Site
  • Michigan
    • Clarkston, Michigan, United States, 48346
      • Clinical Study Site
    • Clinton Township, Michigan, United States, 48038
      • Clinical Study Site
  • Missouri
    • Saint Louis, Missouri, United States, 63117
      • Clinical Study Site
  • Nevada
    • Las Vegas, Nevada, United States, 89106
      • Study Site
  • New Hampshire
    • Portsmouth, New Hampshire, United States, 03801
      • Clinical Study Site
  • New Jersey
    • Berlin, New Jersey, United States, 08009
      • Clinical Study Site
  • New York
    • New York, New York, United States, 10012
      • Clinical Study Site
  • Oregon
    • Portland, Oregon, United States, 97210
      • Clinical Study Site
  • Rhode Island
    • Johnston, Rhode Island, United States, 02919
      • Study Site
  • Texas
    • Austin, Texas, United States, 78759
      • Study Center
    • Houston, Texas, United States, 77004
      • Clinical Study Site
    • Pflugerville, Texas, United States, 78660
      • Clinical Study Site
    • San Antonio, Texas, United States, 78229
      • Study Site
    • San Antonio, Texas, United States, 78213
      • Clinical Study Site
    • San Antonio, Texas, United States, 78229
      • Clinical Study Site
    • Webster, Texas, United States, 77598
      • Study Site
  • Virginia
    • Charlottesville, Virginia, United States, 22911
      • Study Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Evidence of a personally signed and dated written informed consent to participate in the clinical study
2. Male or non-pregnant female adults at least 18 years of age at time of informed consent
3. Chronic plaque-type psoriasis diagnosed for at least 6 months prior to baseline (at time of first study dose)

4. Moderate to severe plaque psoriasis as defined at baseline by:

   1. PASI score of 12 or greater, and
   2. Static PGA score of moderate (3) or severe (4), and
   3. Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater
5. Candidate for systemic therapy or phototherapy
6. Willing to limit ultraviolet light exposure from sunbathing, use of tanning booths, prolonged outdoor exposure, or from other UV light sources during the study.
7. Willing and able to comply with scheduled visits, study assessments and l laboratory tests, and other study procedures

Exclusion Criteria:

1. Positive blood test for HLA-B*5701 allele
2. Currently have forms of psoriasis other than chronic plaque-type, (e.g., guttate, erythrodermic, exfoliative, palmoplantar, pustular), with the exception of nail psoriasis
3. Evidence of drug-induced psoriasis, e.g., a new onset or current exacerbation of psoriasis from beta-blockers, calcium channel inhibitors, antimalarial drugs or lithium
4. Psoriasis flare or rebound within 4 weeks prior to Screening
5. Active inflammatory diseases other than psoriasis that might confound the evaluation of study treatment on signs and symptoms of psoriasis.

6. . Any of the following prohibited treatments that do not meet the specified minimum washout period:

   1. Biologic immunomodulating treatments of brodalumab or ustekinumab within 24 weeks prior to start of study treatment
   2. Biologic immunomodulating treatments such as adalimumab, etanercept, infliximab, ixekizumab, secukinumab or certolizumab pegol within 12 weeks prior to start of study treatment

   3. Systemic immunomodulating treatments other than biologics within 4 weeks prior to start of study treatment, e.g., oral corticosteroids, injectable corticosteroids (intraarticular, intramuscular, cutaneous/subcutaneous or intravenous), methotrexate, cyclosporine, cyclophosphamide, apremilast

      • Inhaled or intranasal corticosteroids with predominantly local effect (e.g., to treat asthma) are allowable
      • Use of corticosteroids in the eye or the ear are allowable

   4. Other systemic treatments for psoriasis within 4 weeks prior to start of study treatment, e.g., retinoids, fumarates

      • Any such treatment used to treat a symptom of psoriasis but not the condition itself (e.g., anti-histamines for pruritus) is not restricted
   5. Photochemotherapy, e.g., Psoralens + UVA phototherapy (PUVA), within 4 weeks prior to start of study treatment
   6. Phototherapy, e.g., UVA, UVB, within 2 weeks prior to start of study treatment

   7. Topical treatments that could affect signs and symptoms of psoriasis within 2 weeks prior to start of study treatment, e.g., corticosteroids, vitamin D analogs, retinoids, pimecrolimus, tacrolimus, tars, keratolytics

      • Allowable exceptions are: low or least potent (Class 6 or 7) topical corticosteroids for use on face, palms, soles, and intertriginous areas only; tar and salicylic acid preparations/shampoos for use on scalp only; bland emollient for use on any body region
7. Past vaccination with live vaccine within 6 weeks prior to start of study treatment, or plans for administration during the study
8. Any investigational or experimental therapy or procedure or participation in any interventional trial within 4 weeks or 5 half-lives (whichever is longer) prior to start of study treatment
9. Women of child-bearing potential who are not using reliable means of contraception, e.g., abstinence, surgical sterilization (hysterectomy and/or bilateral oophorectomy or partner vasectomy) or tubal ligation, double barrier method, oral/ injected/ implanted/ transdermal hormonal contraception, intrauterine device or intrauterine system, throughout study participation, and for 4 weeks after the end of treatment
10. Women of child-bearing potential who are pregnant or nursing (lactating), or planning a pregnancy while participating in the study
11. History of any ongoing, chronic or recurrent infectious disease (with the exception of episodic herpes labialis and herpes genitalis, and vaginal yeast infections)
12. Evidence of tuberculosis infection as defined by a positive QuantiFERON®-TB Gold In-Tube test (QFT-G) at Screening, or subjects with an indeterminate QFT-G test result with any retest result as indeterminate or positive
13. History of either untreated or incompletely treated latent or active tuberculosis infection
14. Ongoing or recent history of any non-psoriatic uncontrolled (in the Investigator's medical opinion) systemic disease, including, but not limited to renal, hepatic, hematologic, gastrointestinal, endocrine, metabolic, pulmonary, cardiac, neurologic, or psychiatric disease. (e.g., A past or current history of hypertension that is controlled with diet and/or medications is not exclusionary.)
15. History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years with the exception of: basal cell or squamous cell carcinoma or actinic keratoses that have been treated or excised with no evidence of recurrence in the past 12 weeks; cervical carcinoma in situ or non-invasive malignant colon polyps that have been removed
16. Active systemic infections during the past two weeks (exception: common cold) prior to start of study treatment or any infection that reoccurs on a regular basis
17. Past medical history of infection with HIV, hepatitis B or hepatitis C
18. History of any allergic reaction to any formulation of abacavir
19. Previous treatment with any abacavir-containing product, e.g., Ziagen®, Epzicom®, or Trizivir®
20. Previous participation in a clinical study of Prurisol
21. Presence of any medical or psychiatric condition that, in the Investgator's opinion, makes it unlikely that the requirements of the protocol will be completed
22. History of alcohol or substance abuse, unless in full remission for more than 6 months prior to start of study treatment
23. Electrocardiogram (ECG) obtained at Screening visit which shows medically relevant abnormalities which may affect subject safety or interpretation of study results

24. Observed clinical laboratory values/abnormalities during Screening that show any one or more of the following:

    1. Screening total white blood cell (WBC) count <2.5 x 10^9/L, or platelets <100 x 10^9/L or neutrophils <1.2 x 10^9/L or hemoglobin <8.5 g/dL
    2. Screening serum creatinine level exceeding 2.0 mg/dL (176.8 µmol/L)
    3. Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels > 2 x ULN
25. Any other severe acute or chronic medical or psychiatric condition or test abnormality(ies) that, in the Investigator's opinion, puts the subject at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Placebo Comparator: Placebo daily Two (2) placebo capsules given twice daily (AM and PM) for 84 (± 2 days	Drug: Placebo; Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
Active Comparator: 300 mg (150 mg BID); Active Comparator: 300 mg of Prurisol daily One (1) capsule containing 100 mg Prurisol and one (1) capsule containing 50 mg of Prurisol given twice (AM and PM) for 84 (± 2) days	Drug: 300 mg (150 mg BID); Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart; Other Names: Prurisol
Active Comparator: 400 mg (200 mg BID); Active Comparator: 400 mg of Prurisol daily Two (2) capsule each containing 100 mg Prurisol given twice daily (AM and PM) for 84 (± 2) days	Drug: 400 mg (200 mg BID); Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart; Other Names: Prurisol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants achieving at least a 75% reduction from baseline in PASI score (PASI75) at Week 12	The Psoriasis Area and Severity Index (PASI) quantifies the severity of psoriasis based on lesion severity and the percent of body surface area affected. It is a composite assessment, across body regions, reflected in a single score: 0 (no disease) to 72 (maximal disease).	12 Weeks
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Reporting of Adverse Events measurements, and reporting of adverse events.	16 Weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of subjects achieving a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline	The static Physician Global Assessment reflects an overall severity of the erythema, induration and scaling across all psoriatic lesions on a 5-point scale, where 0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe.	16 Weeks
PASI75 response at time points through Week 16	The Psoriasis Area and Severity Index (PASI) quantifies the severity of psoriasis based on lesion severity and the percent of body surface area affected. It is a composite assessment, across body regions, reflected in a single score: 0 (no disease) to 72 (maximal disease).	16 Weeks
The actual and change from baseline in patient-reported itch severity score	The severity of itching due to psoriasis will be assessed on a horizontal numeric rating scale, anchored by the terms "No itching" (0) and "Worst possible itching" (10).	16 weeks
Assessment of patient-reported quality of life by the Dermatology Life Quality Index (DLQI)	The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology questionnaire that assesses patient health-related quality of life in adult subjects with skin diseases such as psoriasis	16 Weeks
Assessment of patient-reported quality of life by the Short Form-36 Health Survey (version 2, acute form)	The SF-36 is a widely used general health status questionnaire that assesses 8 domains of functional health and well-being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions	12 Weeks
Assessment of patient-reported quality of life by the Euro-Qol 5 Dimensions Health State Profile	The EQ-5D is a generic instrument designed to assess a subject's general health status. The instrument consists of a questionnaire and a visual analog scale (VAS)	12 Weeks
Assessment of Patient Satisfaction with Study Treatment (PSST)	Overall patient satisfaction with study treatment will be assessed on a 7-point rating scale, with response options range from "very dissatisfied" to "very satisfied"	12 Weeks
Plasma concentrations of Prurisol	Measurement of Prurisol (abacavir glycolate) from a subset of subjects in the trial	4 Weeks
Plasma concentrations of abacavir	Measurement of abacavir, a metabolite of Prurisol, from a subset of subjects in the trial	Timeframe: 4 weeks

Collaborators and Investigators

• Sponsor: Innovation Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2016
• Primary Completion (Actual): November 1, 2017
• Study Completion (Actual): December 1, 2017

Study Registration Dates

• First Submitted: October 14, 2016
• First Submitted That Met QC Criteria: October 27, 2016
• First Posted (Estimate): October 31, 2016

Study Record Updates

• Last Update Posted (Actual): February 13, 2018
• Last Update Submitted That Met QC Criteria: February 9, 2018
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Psoriasis
• Other Study ID Numbers: CTIX-PRU-005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO